Literature DB >> 33806713

Visual Parameters and Retinal Morphology for Polypoidal Choroidal Vasculopathy Pre- and Post-Intravitreal Ranibizumab with or without Photodynamic Therapy: A Short-Term Prospective Study.

Rituparna Ghoshal1, Sharanjeet Sharanjeet-Kaur1, Norliza Mohamad Fadzil1, Somnath Ghosh2, Nor Fariza Ngah3, Roslin Azni Binti Abd Aziz3.   

Abstract

The objective of this study was to compare visual parameters and retinal layers' morphology pre-treatment (baseline) and 6 months post-treatment in polypoidal choroidal vasculopathy (PCV) eyes. A single centre, longitudinal, prospective study was conducted at a public tertiary hospital of Malaysia. Visual parameters including distance and near visual acuity (DVA and NVA), contrast sensitivity (CS), reading speed (RS), and different qualitative and quantitative optical coherence tomography (OCT) parameters were evaluated pre- and 6 months post-treatment. Thirty-three naïve PCV eyes of 32 patients (mean age of 67.62 years) were evaluated pre- and post-treatment of intravitreal ranibizumab with and without photodynamic therapy. After treatment, sub retinal fluid decreased from 27 eyes (84.35%) at baseline to 7 eyes (21.88%) at 6 months while pigment epithelium detachment decreased from 32 eyes (100%) at base line to 15 eyes (46.87%) at 6 months. Mean pre-treatment quantitative morphological OCT retinal parameters including thickness and volume of central sub field, center thickness, center minimum, and maximum thickness reduced significantly. Similarly, all visual parameters including DVA, NVA, CS, and RS showed statistically significant improvement. While 89% of the eyes showed improvement in CS, 78%, 71%, and 65% of the eyes showed improvement in NVA, RS, and DVA, respectively. Thus, CS was the most treatment responsive visual parameter.

Entities:  

Keywords:  combination therapy; polypoidal choroidal vasculopathy; retinal morphology; visual functions

Year:  2021        PMID: 33806713      PMCID: PMC7967335          DOI: 10.3390/ijerph18052581

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


  30 in total

1.  Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study.

Authors:  P Ruamviboonsuk; M Tadarati; S Vanichvaranont; P Hanutsaha; N Pokawattana
Journal:  Br J Ophthalmol       Date:  2010-06-08       Impact factor: 4.638

2.  Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia.

Authors:  Nur Afiqah Mohamad; Vasudevan Ramachandran; Patimah Ismail; Hazlita Mohd Isa; Yoke Mun Chan; Nor Fariza Ngah; Norshakimah Md Bakri; Siew Mooi Ching; Fan Kee Hoo; Wan Aliaa Wan Sulaiman
Journal:  Int J Ophthalmol       Date:  2017-12-18       Impact factor: 1.779

3.  Predictors of visual outcome in eyes with choroidal neovascularization secondary to age related macular degeneration treated with intravitreal bevacizumab monotherapy.

Authors:  Jay Chhablani; Jae Suk Kim; William R Freeman; Igor Kozak; Hai-Yan Wang; Lingyun Cheng
Journal:  Int J Ophthalmol       Date:  2013-02-18       Impact factor: 1.779

4.  Standard measures of visual acuity do not predict drivers' recognition performance under day or night conditions.

Authors:  Joanne M Wood; D Alfred Owens
Journal:  Optom Vis Sci       Date:  2005-08       Impact factor: 1.973

Review 5.  Polypoidal choroidal vasculopathy: clinical features and genetic predisposition.

Authors:  Shigeru Honda; Wataru Matsumiya; Akira Negi
Journal:  Ophthalmologica       Date:  2013-11-21       Impact factor: 3.250

6.  Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics.

Authors:  Kenichiro Sho; Kanji Takahashi; Haruhiko Yamada; Mitsumasa Wada; Yoshimi Nagai; Tsuyoshi Otsuji; Maki Nishikawa; Yumiko Mitsuma; Yukari Yamazaki; Miyo Matsumura; Masanobu Uyama
Journal:  Arch Ophthalmol       Date:  2003-10

7.  Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy.

Authors:  T Y Y Lai; W-M Chan; D T L Liu; F O J Luk; D S C Lam
Journal:  Br J Ophthalmol       Date:  2008-03-20       Impact factor: 4.638

8.  Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy.

Authors:  M Matsuoka; N Ogata; T Otsuji; T Nishimura; K Takahashi; M Matsumura
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

Review 9.  Polypoidal Choroidal Vasculopathy: Definition, Pathogenesis, Diagnosis, and Management.

Authors:  Chui Ming Gemmy Cheung; Timothy Y Y Lai; Paisan Ruamviboonsuk; Shih-Jen Chen; Youxin Chen; K Bailey Freund; Fomi Gomi; Adrian H Koh; Won-Ki Lee; Tien Yin Wong
Journal:  Ophthalmology       Date:  2018-01-10       Impact factor: 12.079

Review 10.  Anti-VEGF Therapy for Neovascular AMD and Polypoidal Choroidal Vasculopathy.

Authors:  Gemmy Chui Ming Cheung; Timothy Y Y Lai; Fumi Gomi; Paisan Ruamviboonsuk; Adrian Koh; Won Ki Lee
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2017-10-03
View more
  1 in total

1.  Baseline Optical Coherence Tomography Parameters That May Influence 6 Months Treatment Outcome of Polypoidal Choroidal Vasculopathy Eyes with Combination Therapy: A Short-Term Pilot Study.

Authors:  Rituparna Ghoshal; Sharanjeet Sharanjeet-Kaur; Norliza Mohamad Fadzil; Somnath Ghosh; NorFariza Ngah; Roslin Azni Abd Aziz
Journal:  Int J Environ Res Public Health       Date:  2021-05-18       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.